<img alt="" src="https://secure.wake4tidy.com/244317.png" style="display:none;">
2017-11-06

Vironova is part of major effort to advance Sweden’s position in biological drugs

Biological drugs hold tremendous potential but are a major challenge to develop. New analytical methods will be needed, including transmission electron microscopy which Vironova is making accessible for the development and quality control processes...

2017-11-06

Scientific publications from Vironova’s ultrastructural pathology collaboration

Vironova is the leader of the research project: “A smart and easy platform to facilitate ultrastructural pathologic diagnoses.” Through our CTO, Ida-Maria Sintorn, PhD, Vironova has the role of project leader as well as scientific contributor.

2017-11-06

Vironova a proud sponsor of the very first Swedish Symposium on Deep Learning

On 20-21 June, the first Swedish Symposium on Deep Learning will take place in Stockholm. Deep learning is a field of machine learning that builds on complex neural networks – originally used to mimic networks of neurons in the brain. In Vironova’s...

2017-11-06

Great success at the Bioprocess International EU Summit in Amsterdam!

A satisfied and happy Vironova team returned from the BPI trade show in Amsterdam last week. Many visitors came to watch a MiniTEM demo in our beautiful booth and an appreciative and enthusiastic crowd enjoyed the presentation “Automated...

2017-11-06

Meaningful insights from the sub-visible space

Don’t miss our talk at BPI European Summit: Automated characterization of gene therapy vectors, VLPs and whole viruses. By Josefina Nilsson, head of EM services. April 25, at 15.00 in the vaccine manufacturing stream. A case study how integrity and...

2017-11-06

Dr Josefina Nilsson, Head of EM services at Vironova shares her thoughts on sub-visible particle characterization

Josefina has extensive experience of characterization of nano-scaled sub-visible particles as a service provider since ten years to the biopharmaceutical industry, from early development to final manufacturing.

2017-11-06

Webinar April 6 - Interview with Vironova founder and CEO Mohammed Homman

Vironova will host a webinar “Automated purity and integrity check of gene therapy vectors” on April 6 at 3 pm CET. (Agenda and registration can be found here.)

2017-11-06

MiniTEM™ event in Leiden attracts key players within gene therapy and vaccine industries

A full-day event including live demo of MiniTEM and presentations showing how to go from manual to automated virus particle characterization attracted more than 10 different companies located in Europe. Invited speaker Vesa Turkki, Senior Scientist...

2017-11-06

Vironova is building a state of the art electron microscopy (EM) facility to meet increasing demand

Vironova has established a growing number of global customers in the highly-regulated and quality demanding pharmaceutical industry, who focus on drug/gene delivery and vaccine development. Currently 7 of the 10 largest biopharmaceutical companies...

2017-11-06

Vironova has filed a US provisional patent for analyzing viral vector content using cryoTEM

Vironova has now filed a patent for quantitative analysis of viral vector content using cryoTEM, a method that has already triggered plenty of interest amongst our customers.